LEUKEMIA & LYMPHOMA SOCIETY®

Gwen Nichols, MD

EVP, Chief Medical Officer, The Leukemia & Lymphoma Society

As The Leukemia & Lymphoma Society's (LLS) Chief Medical Officer (CMO), Gwen Nichols, MD, plays a critical role in advancing cures through a unique combination of clinical, academic and pharmaceutical experience. She oversees LLS's scientific research portfolio, patient services, and policy and advocacy initiatives. Dr. Nichols leads an international team of preeminent leaders in pediatric acute leukemia to conceive, develop and implement LLS PedAL, a first-of-its-kind global master clinical trial and a key component of The Dare to Dream Project, transforming treatment and care for kids with blood cancer.

A physician and scientific researcher, Dr. Nichols has dedicated her career to advancing cures for cancers. Before joining LLS, she was oncology site head of the Roche Translational Clinical Research Center, where she worked to develop new cancer therapies, translating them from the laboratory to clinical trials. Prior to joining Roche in 2007, Dr. Nichols was at Columbia University for more than 10 years, where she served as the director of the Hematologic Malignancies Program.

While at Columbia University, Dr. Nichols maintained an active clinical practice and received the prestigious honors of "Physician of the Year" from Columbia University and the "Humanism in Medicine Award" from the American Association of Medical Colleges.

Laura Di Laurenzio, PhD

Project Team Leader, The Leukemia & Lymphoma Society

Laura Di Laurenzio, PhD, plays a critical role in The Leukemia & Lymphoma Society's (LLS) PedAL Master Clinical Trial – from the development of its complex framework to leading discussions with pharmaceutical, nonprofit and international collaborators including the National Cancer Institute (NCI), Children's Oncology Group (COG) and European Pediatric Acute Leukemia (EuPAL) Foundation. Dr. Di Laurenzio's leadership has helped bring together worldwide leaders in pediatric acute leukemia to develop PedAL, a clinical trial that maximizes clinical trial efficiency, leveraging LLS's unique relationship with key regulatory agencies including the U.S. Food and Drug Administration (FDA).

LLS serves as the single study sponsor for PedAL, and in collaboration with PedAL co-chairs, Dr. Di Laurenzio drove the strategy for and participated in all meetings with the FDA and European Medicines Agency (EMA). Dr. Di Laurenzio also drove the operational framework for PedAL, including contract negotiations and leading scientific meetings with pharmaceutical companies.

Prior to joining LLS in 2018, Dr. Di Laurenzio held various positions at F. Hoffmann-La Roche Inc. (Roche), from project manager to due diligence director to project team leader to senior clinical program leader, and was accountable for the strategic and operational planning, implementation, and delivery of the clinical development within Roche's Early Development portfolio in various therapeutic areas (Primary Care, Oncology, Neuroscience and Ophthalmology). While at Roche, Dr. Di Laurenzio received the Pharma Research & Early Development (pRED) "Leverage External Innovation" Recognition Award for her contribution to the development of two medicines (alectinib and emicizumab). Both products achieved the milestone of transitioning to late-stage development and became marketed therapies.

Dr. Di Laurenzio holds a doctorate in biochemistry from the University of Alberta and a doctorate in chemistry, summa cum laude, from the University of Rome. Her work has been published in *Cancer Chemotherapy Pharmacology*, *The Lancet Oncology* and *Cell*, among other notable journals.

LEUKEMIA & LYMPHOMA SOCIETY®

Julie Guillot

Volunteer Chair, Pediatric Partnerships & Outreach, The Leukemia & Lymphoma Society

Julie Guillot is an advocate and former technology executive with a passion for accelerating progress in childhood cancer. Guillot lost her 9-year-old son, Zach, to acute myeloid leukemia (AML) in 2014 following a four-year struggle across three hospitals. Deeply impacted by this journey, she now works full-time as the volunteer chair of Pediatric Partnerships and Outreach at The Leukemia & Lymphoma Society (LLS), building strategic alliances and support for the new LLS PedAL Master Clinical Trial -- driving a fundamental shift in how pediatric acute leukemia is treated. The trial is part of The Dare to Dream Project, transforming treatment and care for kids with blood cancer.

Guillot brings more than 15 years of experience in the high-tech sector and significant nonprofit expertise to this initiative. Previously, she held executive positions at NetSolve/Cisco Systems, Dell and Accenture, where she led business operations, business process re-engineering activities and large-scale IT system implementations. Today, she leverages these skills to accelerate progress in childhood cancer by identifying and championing the “highest potential, greatest need” projects while fostering collaboration across research funders.

An influential voice in the pediatric cancer community, Guillot has appeared on Good Morning America and penned articles published by Parents.com, STAT News, MIT Technology Review and others. She serves as an advocate on the National Cancer Institute’s (NCI) Childhood Cancer Data Initiative Working Group and Children’s Oncology Group’s (COG) Myeloid Disease Committee. She is also a member of the Coalition Against Childhood Cancer. Highlights of her efforts include spearheading the Target Pediatric AML Project, which raised $8 million for cutting-edge research, and joining Fred Hutchinson Cancer Research Center’s prestigious Nobel Laureates Circle and Board of Ambassadors.

Guillot received her bachelor’s degree in civil engineering from Texas A&M University and lives in Austin, Texas, with her husband, Jeff, and two remaining children – Jake and Lilli.

Andy Kolb, MD

Nemours Children's Health, Delaware, Chief of Oncology and Hematology; Chair of the COG AML Committee; and Co-chair of PedAL

E. Anders (Andy) Kolb, MD, is a board-certified pediatric hematologist/oncologist at Nemours Children's Hospital, Delaware. He joined Nemours Children's Health in 2007 as program director of blood and bone marrow transplantation and is presently chief of the Division of Hematology and Oncology, director of the Nemours Center for Cancer and Blood Disorders, and vice chairman for Research in the Department of Pediatrics at the Sidney Kimmel Medical College at Thomas Jefferson University.

Dr. Kolb also serves as co-chair of The Leukemia & Lymphoma Society PedAL Master Clinical Trial, the first of its kind to fundamentally change how children with acute leukemias are treated. As a member of the leadership team, Dr. Kolb is among the worldwide leaders in pediatric acute leukemia brought in to conceive, develop and implement the groundbreaking master clinical trial, which will reduce logistical barriers and get relapsed patients to trials more quickly. As a member of the executive committee, he contributes to overall strategy of the clinical trial and provides mentorship for early-stage investigators.

Prior to joining Nemours Children's Health, Dr. Kolb was a member of the Pediatric Leukemia and Pediatric Stem Cell Transplantation Services at Memorial Sloan-Kettering Cancer Center in New York City and the director of the Pediatric Preclinical Chemotherapy Testing Laboratory at the Albert Einstein Cancer Center, Albert Einstein College of Medicine in the Bronx. He was also director of the Pediatric Leukemia and Lymphoma Service and Pediatric Stem Cell Transplantation at The Children's Hospital at Montefiore, also in the Bronx.

Dr. Kolb has been an invited lecturer at numerous national and international meetings and is a very active researcher, having been the principal or co-principal investigator of numerous studies and grants, including clinical trials with the Children's Oncology Group (COG); the Nemours NCI Community Oncology Research Program (NCORP); and the Center of Biomedical Research Excellence (COBRE), which recently awarded Nemours Children's Health a $10.5 million grant to establish the Delaware Comprehensive Sickle Cell Research Center.

Todd M. Cooper, DO

Section Chief of Pediatric Oncology, Director of the Pediatric Leukemia/Lymphoma Program and Co-director of the High-Risk Leukemia Program at Seattle Children's

Todd M. Cooper, DO, is an attending physician at Seattle Children's Hospital, professor of pediatrics at the University of Washington School of Medicine and Evan's Family Endowed Chair in Pediatric Cancer. Dr. Cooper is the director of the Pediatric Leukemia/Lymphoma Program and co-director of the High-Risk Leukemia Program.

A member of The Leukemia & Lymphoma Society's (LLS) PedAL leadership, Dr. Cooper is part of team responsible for launching the first-of-its-kind global master clinical trial to change the treatment paradigm for acute leukemia. In this role, he is working to find safer, more effective treatments through his intimate involvement in designing and leading the clinical trials and determining what new therapies should be tested. In this role, he has engaged with the U.S. Food & Drug Administration (FDA) and European Medicines Agency (EMA) in discussing individual new drugs and general clinical trial designs for children with relapsed acute leukemia.

Dr. Cooper's interests and expertise focus on the development of new therapeutic strategies for the treatment of acute leukemia in children. Prior to coming to Seattle, Dr. Cooper developed and provided leadership for Phase I/Developmental Therapeutics programs at the University of Alabama at Birmingham and Children's Healthcare of Atlanta/Emory University.

Dr. Cooper has led Phase I studies of new agents for relapsed acute leukemia in a variety of national consortia including the Therapeutic Advances for Childhood Leukemia (TACL) Consortium, Pediatric Oncology Experimental Therapeutics Investigator Consortium (POETIC) and the Children's Oncology Group (COG) Consortium. Dr. Cooper serves as the chair of the COG Acute Myeloid Leukemia (AML) New Agents Committee and actively collaborates internationally to help maintain a cohesive strategy for the treatment of children with acute leukemia. Dr. Cooper leads COG AAML1831, a COG Phase III study for newly diagnosed children with AML.

Jason Farrar, MD

Director, Leukemia/Lymphoma Program at Arkansas Children's Hospital

Dr. Jason Farrar directs the leukemia/lymphoma program Arkansas Children's Hospital, the first site that will enroll patients in the PedAL trial. He is dedicated to bringing new, safer therapies to children with leukemias and is excited about PedAL's potential to replace one-size-fits-all chemotherapy with treatments tailored to each patient's disease. He also is a faculty member at the University of Arkansas for Medical Sciences, where he went to medical school. There, he found his niche in cancer through a summer research program studying a high-risk chromosomal abnormality in infants with leukemia. Dr. Farrar completed his pediatrics residency at the Children's Hospital of Wisconsin followed by a pediatric hematology/oncology fellowship in a joint program at Johns Hopkins University and the National Cancer Institute (NCI).

Dr. Farrar's research focus is on genetic changes that impair bone marrow function, including childhood acute myeloid leukemia (AML) and the leukemia-prone bone marrow failure syndromes. His work with the Children's Oncology Group (COG)/NCI TARGET (Therapeutically Applicable Research to Generate Effective Treatments) initiative described the first comprehensive map of the unique genetic changes underlying childhood AML. As part of ongoing work in the cooperative group, Dr. Farrar helps leverage clinical data and biological specimens from large-scale research studies in an effort to identify genetic drivers of childhood leukemia and translate these into therapies that can improve treatment outcomes.